Welcome to Smole Biopharma

A brighter future for those fighting cancer

Now Ministry of Corporate Affairs Approved

Mission

Smole Biopharma is the first to utilize the small molecule for multi-targets on unique characteristics of cancer cells, providing a clear differentiation between healthy and malignant tissue in the operating room. The benefit of the multi-targeting small molecule is that they move through the body quickly and binds selectively with cancer cells/tissues. This quick action allows for flexible dosing schedules prior to surgery and minimal impact to work flow in the operating room.

Vision

Our vision is to illuminate different stages and types of cancers intraoperatively so it can be removed completely. Because the imaging system, coupled with our bright dye, operates in the near-infrared spectrum, it optimizes visibility even in lesions that are below the tissue surface. Once our molecule reaches their target they are endocytosed and remain inside the cancer cells throughout the length of the procedure. SMOLE Biopharma will explore on developing universal multi-receptor targeted intraoperative molecular imaging agents are being to bind different stages and types of cancerous tissues. This helping surgeons to better see lesions in real-time as they operate, enabling the detection of more and complete removal of cancers up to cellular level.

Highlights

Our Latest News